Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia

Diop, Fary; Moia, Riccardo; Favini, Chiara; Spaccarotella, Elisa; De Paoli, Lorenzo; Bruscaggin, Alessio; Spina, Valeria; Terzi-di-Bergamo, Lodovico; Arruga, Francesca; Tarantelli, Chiara; Deambrogi, Clara; Rasi, Silvia; Adhinaveni, Ramesh; Patriarca, Andrea; Favini, Simone; Sagiraju, Sruthi; Jabangwe, Clive; Ahmed Kodipad, Ahad; Peroni, Denise; Romana Mauro, Francesca; Del Giudice, Ilaria; Forconi, Francesco; Cortelezzi, Agostino; Zaja, Francesco; Bomben, Riccardo; Maria Rossi, Francesca; Visco, Carlo; Chiarenza, Annalisa; Matteo Rigolin, Gian; Marasca, Roberto; Coscia, Marta; Perbellini, Omar; Tedeschi, Alessandra; Laurenti, Luca; Motta, Marina; Donaldson, D.; Weir, Philip; Mills, Ken; Thornton, Patrick; Lawless, Sarah; Bertoni, Francesco; Del Poeta, Giovanni; Cuneo, Antonio; Follenzi, Antonia; Gattei, Valter; Boldorini, Renzo; Catherwood, Mark; Deaglio, Silvia; Foà, Robin; Gaïdano, Gianluca; Rossi, Davide

doi:10.3324/haematol.2019.219550

Public

Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia

Published in Haematologica • Aug 1, 2019

Authors:

Fary Diop

Riccardo Moia

Chiara Favini

Abstract

BIRC3 is a recurrently mutated gene in chronic lymphocytic leukemia (CLL) but the functional implications of BIRC3 mutations are largely unexplored. Furthermore, little is known about the prognostic impact of BIRC3 mutations in CLL cohorts homogeneously treated with first-line fludarabine, cyclophos...

Subject

IGHV@

Chronic lymphocytic leukemia

Fludarabine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!